Methods for detecting retroviruses

• US 7,566,532 B1
• Filed: 06/28/2005
• Issued: 07/28/2009
• Est. Priority Date: 07/02/2004
• Status: Expired due to Fees

• Current Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: Platt, Jamie L., Exner, Maurice
• Primary Examiner(s): Mosher; Mary E
• Assistant Examiner(s): SNYDER, STUART
• Application Number:
  US11/169,287
• Time in Patent Office: 1,491 Days
• Field of Search: None
• US Class Current: 435/5
• CPC Class Codes: C12Q 1/703 Viruses associated with AIDS

Abstract

Disclosed is a method for detecting human retroviral nucleic acids such as human immunodeficiency virus type I (HIV-1) nucleic acid, human T-cell leukemia virus type I (HTLV-I) nucleic acid, and human T-cell leukemia virus type II (HTLV-II) nucleic acid in a sample. In the method, the sample is treated with reverse transcriptase to generate cDNA, and the cDNA is subsequently analyzed to detect HIV-1, HTLV-I, and HTLV-II. The method may include performing PCR and the method may utilize specific primers. In addition, the method may utilize HTLV linkers that facilitate PCR amplification and sequencing. The cDNA may be treated with restriction enzymes before or after PCR amplification to facilitate sequencing and detection of HIV-1, HTLV-I, or HTLV-II nucleic acid.

Claims

1. A method for detecting in a single assay whether a sample contains an HIV retrovirus and/or an HTLV retrovirus, the method comprising:

a) preparing cDNA by reverse transcribing nucleic acids in the sample;

b) ligating a first oligonucleotide linker to the cDNA to form an anchored-end cDNA;

c) amplifying the anchored-end cDNA to form amplified cDNA using primers that specifically anneal to the first oligonucleotide linker;

d) treating the amplified cDNA with a restriction enzyme to generate cDNA fragments;

e) ligating a second oligonucleotide linker to the cDNA fragments to form anchored-end cDNA fragments;

f) sequencing the anchored-end cDNA fragments using sequencing primers that specifically anneal to the second oligonucleotide linker; and

g) comparing the sequences with the known nucleotide sequences of HIV and/or HTLV retroviruses to determine if the sample contained an HIV retrovirus and/or an HTLV retrovirus.

2. The method of claim 1, wherein the HIV retrovirus is HIV-1.

3. The method of claim 1, wherein the HTLV retrovirus is HTLV-I.

4. The method of claim 1, wherein the HTLV retrovirus is HTLV-II.

5. The method of claim 1, wherein the second oligonucleotide linker comprises HTLV nucleic acid.

6. The method of claim 1, further comprising contacting the sample with an immobilized nucleic acid to capture the HIV retrovirus and/or an HTLV retrovirus nucleic acid in the sample prior to step a).

7. The method of claim 6, wherein the immobilized nucleic acid specifically anneals to at least a portion of the pol gene of HIV-1, HTLV-I, and HTLV-II.

8. The method of claim 1, wherein the first oligonucleotide linker comprises HTLV nucleic acid.

9. The method of claim 1, wherein one or more primers for reverse transcribing, and primers for amplifying and sequencing and the linkers are about 10 to about 100 nucleotides in length.

10. The method of claim 1, wherein one or more primers for reverse transcribing, and primers for amplifying and sequencing and the linkers are about 10 to about 40 nucleotides in length.

11. The method of claim 1, wherein one or more primers for reverse transcribing are specific for HIV-1 nucleic acid, HTLV-I nucleic acid, and HTLV-II nucleic acid.

12. The method of claim 1, wherein one or more primers for reverse transcribing, and primers for amplifying and sequencing comprise a nucleotide other than adenine (A), cytosine (C), thymidine (T), or guanine (G).

13. The method of claim 12, wherein one or more primers for reverse transcribing, and primers for amplifying and sequencing comprise inosine.

14. The method of claim 1, wherein the first oligonucleotide linker and the second oligonucleotide linker are the same.

15. The method of claim 1, wherein the first oligonucleotide linker and the second oligonucleotide linker are different.